Product Description
GX-G6 is long-acting GLP-1 based on Genexines proprietary hyFc Platform technology for type 2 diabetes (T2D) targeting both weekly and twice-monthly regimen compared to conventional daily therapeutics.
Mechanisms of Action: GLP-1 Agonist
Novel Mechanism: No
Modality: Peptide/Protein
Route of Administration: N/A
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Genexine, Inc.
Company Location:
Company Founding Year: None
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Type 2 Diabetes
Phase 1: General Diabetes|Healthy Volunteers
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT03651466 |
GX-G6_HV1 | P1 |
Completed |
General Diabetes|Healthy Volunteers |
2018-06-06 |
2019-03-22 |
Treatments |
|
NCT03962010 |
GX-G6-002 | P2 |
Unknown status |
Type 2 Diabetes |
2022-06-01 |
43% |
2022-07-07 |
Recent News Events
Date |
Type |
Title |
|---|---|---|
|
07/20/2021 |
News Article |
Type 2 Diabetes Pipeline Holds a Potential Future in Treatment Scenario. |